CCO Medical Specialties Podcast: Recent Episodes
Clinical Care Options
Weekly updates on new data, current advances, and best practices in patient care for a variety of medical specialties including NASH, diabetes, muscular dystrophy, and more from Clinical Care Options. Gain practical strategies and earn CME/CE credit for selected episodes.
Four inflammatory bowel disease (IBD) experts explore case-based strategies for optimizing advanced IBD therapy and long-term disease management early in real-world practice. They discuss practical approaches for implementing treat-to-target via strategic treatment sequencing, therapeutic drug monitoring, and maintenance approaches while supporting individualized, evidence-based care for patients with IBD.
Presenters
Jessica R. Allegretti, MD, MPH, FACG, AGAF
Medical Director, Infusion Services
Director, Crohn’s and Colitis Center
Director of Clinical Research
Director, Fecal Microbiota Transplant Program
Division of Gastroenterology, Hepatology and Endoscopy
Brigham and Women’s Hospital
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts
Jordan E. Axelrad, MD, MPH, AGAF, FACG, FCCF
Co-Director, Inflammatory Bowel Disease Center at NYU Langone Health
Associate Professor of Medicine
Division of Gastroenterology and Hepatology
NYU Grossman School of Medicine
New York, New York
Russell D. Cohen, MD, FACG, AGAF
Professor of Medicine, Pritzker School of Medicine
Co-Director, Digestive Diseases Center
Clinical Director, Inflammatory Bowel Disease Center
Co-Director, Advanced IBD Fellowship Program
The University of Chicago Medicine
Chicago, Illinois
Amy Stewart, MSN, FNP-C
Lead Advanced Practice Provider
Capital Digestive Care
Washington, DC
Link to full program:
https://bit.ly/4wvm7l4
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
As current understandings of obesity (ie, a chronic disease requiring long-term management) are adopted across the world, screening and treatment can no longer follow a one-size-fits-all approach. Listen in as 3 global experts in obesity medicine highlight the emerging evidence from recent conferences that are changing real-world practice today. Learn how the latest findings apply to specific patient populations across the United States, Europe, and Asia as well as why healthcare professionals should individualize treatment based on patient preferences and relevant risk factors.
Presenters:
Stephano Del Prato, MD
Professor Emeritus of Endocrinology
University of Pisa
Pisa, Italy
Soo Lim, MD, PhD
Professor of Medicine
Department of Internal Medicine
Seoul National University College of Medicine and Seoul National University Bundang Hospital
Seoul, South Korea
Donna H. Ryan, MD
Professor Emerita
Pennington Biomedical Research Center
Louisiana State University
New Orleans, Louisiana
Link to full program:
https://bit.ly/4pwFhEo
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Multispecialty Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this podcast, Jennifer Green, MD, and Jay H. Shubrook, DO, FAAFP, FACOFP, share strategies for integrating incretin-based therapies in type 2 diabetes (T2D) management in the primary care setting, including:
- Importance of moving beyond a glucose-centric approach to T2D care
- Current evidence for incretin-based therapies in T2D
- Rationale for integrating these therapies into the primary care setting
- Shared decision-making strategies to discuss optimal T2D treatment options with patients
- Timing for endocrinology referral
Presenters:
Jennifer Green, MD
Professor of Medicine
Division of Endocrinology
Duke Clinical Research Institute
Duke University School of Medicine
Durham, North Carolina
Jay H. Shubrook, DO, FAAFP, FACOFP
Professor, Diabetologist
Department of Clinical Sciences and Community Medicine
Touro University California, College of Osteopathic Medicine
Vallejo, California
Full program link:
https://bit.ly/4uSKCqv
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Multispecialty Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Listen in as Nancy Reau, MD, reviews key highlights of the most impactful primary biliary cholangitis (PBC) research and gain insights on how to apply these new advances to clinical practice.
Topics covered include:
- Treatment Goals
- Long-term Data With PPAR Agonists
- Investigational Therapies for Pruritus
Presenter:
Nancy Reau, MD
Professor of Medicine
Richard B. Capps Chair of Hepatology
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center
Chicago, Illinois
To download the accompanying slides, visit the program page for this episode:
https://bit.ly/4b2d6YD
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Listen in as Jay H. Shubrook, DO, FACOFP, FAAFP, and Chrisopher Weber, MD, FAAP, FACP, CSCS, daBOM, FOMA, discuss the latest advances in caring for patients with overweight or obesity in the primary care setting, including:
- The Lancet Commission’s new obesity definitions and diagnostic criteria
- Key data on incretin-based antiobesity medications like semaglutide and tirzepatide
- Best practices for patient discussions
- Strategies for incorporating new evidence in your primary care practice
Presenters
Jay H. Shubrook, DO, FACOFP, FAAFP
Professor and Diabetologist
Department of Clinical Sciences and Community Health
Touro University California College of Osteopathic Medicine
Vallejo, California
Christopher Weber, MD, FAAP, FACP, CSCS, daBOM, FOMA
Bariatric Services Medical Director, Ascension Wisconsin
Obesity Medicine Director, Ascension Columbia St Mary’s Bariatric Center
Trustee, Obesity Medicine Association
Adjunct Assistant Professor of Pediatrics
Medical College of Wisconsin
Milwaukee, Wisconsin
Link to full program:
https://bit.ly/4rG7QQp
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Historically, key symptoms of primary biliary cholangitis (PBC), such as pruritus and fatigue, have been understudied and undertreated. Listen now to learn how symptom management should be considered independently of PBC management, and how new therapeutic agents can help.
Topics covered include:
- Mechanisms of pruritus and fatigue in PBC
- Nonpharmacologic treatment options
- An overview of clinical trial data supporting second-line agents for symptom management:
- Bezafibrate
- Elafibranor
- Seladelpar
- Investigational agents:
- Volixibat
- Linerixibat
- Setanaxib
This episode is the third of 3 recap podcasts, featuring audio from our live satellite symposium, Raising the Bar: Innovations in PBC Care. For the full on-demand webcast of this satellite symposium, and to download the accompanying slides, visit the program page for this episode:
https://bit.ly/44ZJ5os
Presenters:
Christopher L. Bowlus, MD
Lena Valente Professor and Chief
Division of Gastroenterology and Hepatology
School of Medicine
University of California Davis
Sacramento, California
Aparna Goel, MD
Clinical Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Stanford University
Palo Alto, California
Aliya F. Gulamhusein, MD,
MPH, FRCPC
Professorship in PSC Research
Clinician Investigator, Toronto General Hospital
Assistant Professor, University of Toronto
Division of Gastroenterology and Hepatology
University Health Network
Toronto, Canada
Get access to all of our new episodes by subscribing to the Decera Clinical Education Medical Specialties Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
New therapeutic agents for second-line treatment are raising the bar for primary biliary cholangitis (PBC) management. Listen now to learn how to incorporate these new agents into clinical practice and how these agents will impact attainment of treatment goals.
Topics covered include:
- Available agents for second-line treatment of PBC
- An overview of clinical trial data supporting second-line agents:
- Obeticholic acid (OCA)
- Bezafibrate
- Elafibranor
- Seladelpar
This episode is the second of 3 recap podcasts, featuring audio from our live satellite symposium, Raising the Bar: Innovations in PBC Care. For the full on-demand webcast of this satellite symposium, and to download the accompanying slides, visit the program page for this episode: https://bit.ly/48MEc3r
Presenters:
Christopher L. Bowlus, MD
Lena Valente Professor and Chief
Division of Gastroenterology and Hepatology
School of Medicine
University of California Davis
Sacramento, California
Aparna Goel, MD
Clinical Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Stanford University
Palo Alto, California
Aliya F. Gulamhusein, MD, MPH, FRCPC
Professorship in PSC Research
Clinician Investigator, Toronto General Hospital
Assistant Professor, University of Toronto
Division of Gastroenterology and Hepatology
University Health Network
Toronto, Canada
Get access to all of our new episodes by subscribing to the Decera Clinical Education Medical Specialties Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Advancements in our understanding of primary biliary cholangitis (PBC) and new therapeutic agents have reshaped the care landscape of PBC. Listen now to learn how these developments are helping to redefine and elevate treatment goals. Topics covered include:
- How and when to assess treatment response
- Risk factors in PBC
- Biochemical treatment response and fibrosis stage as predictors of transplant-free survival
- Dynamics of liver stiffness measurements and clinical outcomes in PBC
- The importance of bilirubin and alkaline phosphatase normalization
This episode is the first of 3 recap podcasts, featuring audio from our live satellite symposium, Raising the Bar: Innovations in PBC Care. For the full on-demand webcast of this satellite symposium, and to download the accompanying slides, visit the program page for this episode: https://bit.ly/44ZJ5os
Presenters:
Christopher L. Bowlus, MD
Lena Valente Professor and Chief
Division of Gastroenterology and Hepatology
School of Medicine
University of California Davis
Sacramento, California
Aparna Goel, MD
Clinical Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Stanford University
Palo Alto, California
Aliya F. Gulamhusein, MD, MPH, FRCPC
Professorship in PSC Research
Clinician Investigator, Toronto General Hospital
Assistant Professor, University of Toronto
Division of Gastroenterology and Hepatology
University Health Network
Toronto, Canada
Get access to all of our new episodes by subscribing to the Decera Clinical Education Medical Specialties Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Join expert faculty, Dr Alan Bonder and Dr Stuart Gordon, to learn more about key gaps in PBC management and how these shortfalls can be addressed through identification of appropriate biochemical goals, proper assessment and management of PBC symptoms, and current second-line therapies.
Presenters:
Alan Bonder, MD, AGAF
Associate Professor of Medicine
Medical Director of Liver Transplant
Beth Israel Deaconess Medical Center
Department of Gastroenterology
Harvard Medical School
Boston, Massachusetts
Stuart C. Gordon, MD, FAASLD
Professor of Medicine
Wayne State University School of Medicine
Professor of Medicine
Michigan State University College of Medicine
Henry Ford Health
Detroit, Michigan
Link to full program:
https://bit.ly/3M29pI1
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Recent advances in primary biliary cholangitis (PBC) care have resulted in a new focus on personalized care and symptom management. Tune in to learn from patient advocate, Maria G. Morais, RN, how you can integrate patient insights and priorities into treatment plans for PBC. Topics covered include:
- The Canadian PBC Society Survey: Comorbidities and Treatment Goals
- Defining and Achieving Goal-Driven Care for PBC
- Recent Advances in PBC Management
- Newer Agents for Second-line Treatment of PBC
Presenters:
Maria G. Morais, RN
PBC Transplant Patient
VP Patient Advocacy
Canadian PBC Society
Toronto, Canada
Link to full program:
https://bit.ly/44ySoL3
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
| Tune in to listen as expert faculty, Dr Christopher L. Bowlus and Dr Sonal Kumar, discuss recent developments in treating primary biliary cholangitis (PBC) with new and emerging agents, as well as strategies to integrate these advances into clinical practice.Topics covered include: * Methods of Assessing PBC Disease Progression * Newer Agents for Second-line Treatment of PBC * Prioritizing Symptom Management and Quality of Life With PBC Treatment
Presenters:Christopher L. Bowlus, MDLena Valenta Professor and ChiefDivision of Gastroenterology and HepatologySchool of Medicine University of California Davis Sacramento, CaliforniaSonal Kumar, MD, MPHAssistant Professor of MedicineDivision of Gastroenterology and HepatologyWeill Cornell Medical CollegeNew York, New YorkLink to full program: https://bit.ly/43nHx6UGet access to all of our new podcasts by subscribing to the CCO Medical Specialties Podcast on Apple Podcasts, YouTube Music, or Spotify. |
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Listen as pulmonologist Peter Dicpinigaitis discusses his approach to the diagnosis and management of patients with refractory chronic cough in the context of a clinically relevant case and provides insights regarding emerging therapies.
Presenter
Peter Dicpinigaitis, MD
Professor of Medicine
Albert Einstein College of Medicine
Division of Critical Care Medicine
Montefiore Medical Center
Director, Montefiore Cough Center
Bronx, New York
Link to full program:
https://bit.ly/4kweynG
Listen as Michael S. Benninger, MD, describes his approach to the diagnosis and management of chronic cough and refractory chronic cough in the context of a clinically relevant case.
Presenter
Michael S. Benninger, MD
Professor of Otolaryngology-Head and Neck Surgery
Lerner College of Medicine
The Cleveland Clinic
President, International Association of Phonosurgery
Cleveland, Ohio
Link to full program:
https://bit.ly/4kweynG
Listen in as Joseph Kim, MD, MPH, MBA, and Colten Bracken, MD, FAAFP, discuss how to integrate comprehensive diabetes management to improve the quality of their obesity care delivery, including:
- Documenting obesity as a diagnosis for patients with diabetes when appropriate
- Streamlining processes to ensure patients return for follow-up
- Dedicating a care manager to initiate patient outreach
- Implementing pharmacotherapy strategies to help patients control their A1C and achieve weight loss simultaneously.
Presenters
Joseph Kim, MD, MPH, MBA
President
Q Synthesis, LLC
Newtown, Pennsylvania
Colten Bracken, MD, FAAFP
Board of Directors for RHAU & UAFP
Owner/Medical Director
Main Street Family Medicine, PLLC
Enterprise, Utah
Link to full program:
https://bit.ly/3IBFZi5
In this episode, Palak J. Trivedi, BSc, MBBS, PhD, MRCP, ESEGH, discusses the most recent developments in primary biliary cholangitis (PBC) treatment, including cutting-edge data on new and emerging agents and how these updates may be integrated into your practice. Topics include:
- Steatotic liver disease and PBC
- Vibration-controlled transient elastography (VCTE) and discordant biochemical responses in PBC
- PPAR agonists and IBATs for PBC treatment
Presenter:
Palak J. Trivedi, BSc, MBBS, PhD, MRCP, ESEGH
Associate Professor
NIHR Birmingham BRC
University of Birmingham
Consultant Hepatologist, Liver Unit
University Hospitals Birmingham
Birmingham, United Kingdom
Link to full program:
https://bit.ly/44ySoL3
Follow along with the slides:
https://bit.ly/3IvwQrj
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify
.
In this episode, Daniel C. Butler, MD, and Shawn G. Kwatra, MD, discuss the practical considerations for using IL-13 inhibitors to treat patients with moderate to severe atopic dermatitis, including:
- Patient candidacy considerations
- Treatment advancement strategies that go beyond topical therapies
- The importance of patient-centered care that address patients’ fears and needs
- A detailed patient case to highlight take home points
Presenter
Daniel C. Butler, MD
Assistant Dean Student Affairs
University of Arizona College of Medicine – Tucson
Tucson, Arizona
Shawn G. Kwatra, MD
Dr. Joseph W. Burnett Endowed Professor and Chair
Department of Dermatology
University of Maryland School of Medicine
Baltimore, Maryland
Program page:
https://bit.ly/4kTP04D
In this episode, Andrew F. Alexis, MD, MPH; Daniel C. Butler, MD; and Shawn G. Kwatra, MD, discuss IL-13 inhibition for treating patients with moderate to severe atopic dermatitis (AD), including:
- The available biologic therapies that specifically target IL-13
- Where these agents fall in the 2024 American Academy of Dermatology treatment algorithm
- How these agents compare to other AD therapies like topical corticosteroids and oral JAK inhibitors
- A detailed patient case to highlight take home points
Presenter
Andrew F. Alexis, MD, MPH
Professor of Clinical Dermatology
Weill Cornell Medical College
New York, New York
Daniel C. Butler, MD
Assistant Dean Student Affairs
University of Arizona College of Medicine – Tucson
Tucson, Arizona
Shawn G. Kwatra, MD
Dr. Joseph W. Burnett Endowed Professor and Chair
Department of Dermatology
University of Maryland School of Medicine
Baltimore, Maryland
Program page:
https://bit.ly/4kTP04D
Listen in as Joseph Kim, MD, MPH, MBA; Manish Shah, MD; Martha Grugel, MA, discuss how they manage the prior authorization process for antiobesity agents to improve the quality of their care delivery, including:
- The information to collect during patient visits
- The available resources to help you submit prior authorizations
- The supporting documents that are often necessary to accompany prior authorizations
- How to address denials and appeals
- When to access manufacturer-based or foundation-based financial assistance
Presenters
Joseph Kim, MD, MPH, MBA
President
Q Synthesis, LLC
Newtown, Pennsylvania
Manish Shah, MD
Clinical Associate Faculty MS1 Preceptor
University of Florida College of Medicine
Gainesville, Florida
Martha Grugel, MA
Medical Assistant
Wesley Chapel, Florida
Link to full program:
https://bit.ly/45P0v8z
| In this episode, Andrew F. Alexis, MD, MPH, and Daniel C. Butler, MD, discuss the immunopathogenesis and role of IL-13 in atopic dermatitis (AD), including:* Contributors to epidermal barrier dysfunction (eg, environmental triggers) * IL-13 as a key cytokine in AD pathogenesis * Targeted AD therapies that inhibit IL-13 * A detailed patient case to highlight take-home points
PresenterAndrew F. Alexis, MD, MPHProfessor of Clinical DermatologyWeill Cornell Medical College New York, New YorkDaniel C. Butler, MDAssistant Dean Student AffairsUniversity of Arizona College of Medicine – TucsonTucson, ArizonaProgram page: https://bit.ly/4kTP04D |
In this podcast, Anne E. O’Donnell, MD, discusses the latest advances and treatment strategies for patients with non–cystic fibrosis bronchiectasis (NCFBE), including:
- Airway clearance as a foundation of NCFBE management
- Strategies to address inflammation and exacerbations
- Emerging therapies in clinical development
- How to individualize treatment to NCFBE phenotypes and endotypes
Presenter
Anne E. O’Donnell, MD
Professor of Medicine
The Nehemiah and Naomi Cohen Chair in Pulmonology Disease Research
Chief, Division of Pulmonary, Critical Care and Sleep Medicine
Georgetown University Medical Center
Washington, DC
Program page:
https://bit.ly/4mZbYsm
In this podcast, Ty J. Gluckman, MD, MHA, discusses the pivotal phase III FINEARTS-HF trial and how the treatment landscape is evolving for patients with heart failure (HF) with mildly reduced or preserved ejection fraction, including:
- The emerging role of mineralocorticoid receptor antagonists in HF care
- Finerenone’s efficacy in reducing composite cardiovascular death and worsening HF events
- Why safety must be monitored, especially considering hyperkalemia risk
- Where HF guideline recommendations lack compared with the current evidence
Presenter
Ty J. Gluckman, MD, MHA
Medical Director, Center for Cardiovascular Analytics, Research, and Data Science (CARDS)
Providence Heart Institute
Providence Health System
Portland, Oregon
Program page:
https://bit.ly/448XcH0
| In this podcast, Brett M. Elicker, MD, and David E. Griffith, MD, ATSF, FACCP, FRSM, discuss the pathophysiology of non–cystic fibrosis bronchiectasis (NCFBE), the patient burden, and best practices with diagnosing NCFBE, including:* The vicious vortex of NCFBE (ie, airway dysfunction, inflammation, infection) * Cough as the most significant symptom and burden * Imaging bronchiectasis with classic and inflammatory findings * Differentiating the causes of NCFBE to inform patient care
PresentersBrett M. Elicker, MDProfessor of Clinical RadiologyChief, Cardiothoracic Imaging DivisionDepartment of Radiology & Biomedical ImagingUniversity of California, San FranciscoSan Francisco, CaliforniaDavid E. Griffith, MD, ATSF, FACCP, FRSMProfessor of MedicineDivision of Mycobacterial and Respiratory DiseasesDepartment of MedicineNational Jewish HealthDenver, ColoradoProgram page: https://bit.ly/4mZbYsm |
Listen in as Joseph Kim, MD, MPH, MBA, interviews Natalie, Orbach, PA-C, to learn about how she implemented patient-centered and individualized treatment plans to improve obesity care at her practice, including
- Discussing weight and how nutrition, physical activity, mental health, and pharmacotherapy strategies can help
- Meeting patients where they are at and offering slow, incremental changes that support long-term outcomes
- Referring patients to community resources and other professionals as need
- Sharing lessons learned for those interested in implementing similar strategies in their practice
Presenter
Joseph Kim, MD, MPH, MBA
President
Q Synthesis, LLC
Newtown, Pennsylvania
Natalie Orbach, PA-C
Physician Assistant
Feirtag & Ramos, PA
Lutherville, Maryland
Link to full program:
https://bit.ly/45P0v8z
Listen as Michael S. Blaiss, MD provides case-based perspectives on chronic cough recognition, burden, management, and pathophysiology and describes the evolving treatment landscape for refractory chronic cough.
Presenter
Michael S. Blaiss, MD
Clinical Professor of Pediatrics
Division of Allergy-Immunology
Medical College of Georgia at Augusta University
Augusta, Georgia
Link to full program:
https://bit.ly/4kweynG
| Listen in as Paula Henao, MD; Rohit Loomba, MD, MHSc; Cheryl Pirozzi, MD, MS; and Corinne Young, NP, FCCP, discuss their screening and monitoring strategies for patients with alpha-1 antitrypsin deficiency, including:* Why early detection is key for improving patient outcomes * How to monitor through use of noninvasive imaging and biopsy per guideline recommendations * How to coordinate patient care to provide much-needed multidisciplinary care * What therapies in the pipeline could transform the treatment landscape for this genetic disease
PresentersPaula Henao, MDAssistant Professor of MedicineDivision of Pulmonary, Allergy and Critical Care MedicinePenn State Hershey Medical CenterHershey, PennsylvaniaRohit Loomba, MD, MHScProfessor of MedicineChief, Division of Gastroenterology and HepatologyDirector, MASLD Research CenterUniversity of California, San DiegoSan Diego, CaliforniaCheryl Pirozzi, MD, MSAssociate Professor of Internal MedicineDivision of Pulmonary and Critical Care MedicineUniversity of UtahSalt Lake City, UtahCorinne Young, NP, FCCPPresident/FounderAssociation of Pulmonary Advanced Practice ProvidersColorado Springs, ColoradoLink to full program: https://bit.ly/4dgCRnq |
Listen in as Joseph Kim, MD, MPH, MBA, interviews Sejal Desai, MD, DABOM, to learn about how she implemented virtual support groups to improve obesity care at her practice, including:
- Dedicating 5 support groups with chat features to obesity-specific topics (eg, sleep, nonscale wins)
- Moderating these chats to ensure no misinformation is shared and a positive, safe space is maintained
- Expanding to include other virtual options that allow patients to engage more in their care
- Utilizing free and subscription-based services to aid in marketing efforts
- Sharing lessons learned for those interested in implementing similar virtual options for their patients
Presenters
Joseph Kim, MD, MPH, MBA
President
Q Synthesis, LLC
Newtown, Pennsylvania
Sejal Desai, MD, DABOM
Board-Certified Obesity Medicine Physician
Owner & Medical Director
Tula Medical Weight Loss & Wellness
Katy, Texas
Link to full program:
https://clinicaloptions.com/content/qi-resource-hub
Listen in as Joseph Kim, MD, MPH, MBA, interviews Sophia Kwon, MD, to learn about how she implemented a documentation shortcut at her institution to improve obesity care, including:
- Creating an obesity checklist within the electronic health record
- Training staff to correctly use this checklist and broach obesity topics with patients
- Garnering feedback to ensure this checklist did not add to note fatigue or burnout among staff
- Sharing lessons learned for others interested in implementing a similar documentation shortcut
Presenter
Joseph Kim, MD, MPH, MBA
President
Q Synthesis, LLC
Newtown, Pennsylvania
Sophia Kwon, MD
Internal Medicine Attending
Riverside University Health System Attending
Loma Linda University Health Associate Faculty
Loma Linda, California
Link to full program:
https://clinicaloptions.com/content/qi-resource-hub
In this episode, Dr Gideon Hirschfield meets with patient advocate Jess Schnur to discuss challenges related to the diagnosis and management of primary biliary cholangitis (PBC) to provide actionable strategies for healthcare professionals to incorporate into patient care, including:
- Disease concerns and frequently asked questions from a patient perspective
- Managing symptoms
- Treatment options and supportive care
- Importance of awareness and education
Presenters:
Gideon Hirschfield, MA, MB BChir, FRCP, PhD
Lily and Terry Horner Chair in Autoimmune Liver Disease Research
Professor, Division of Gastroenterology and Hepatology
University of Toronto
Director, The Autoimmune and Rare Liver Disease Programme
Director, Francis Family Liver Clinic
Toronto General Hospital, University Health Network
Ontario, Canada
Jess N. Schnur, BSN-RN
National PBC Patient Advocate
American Liver Foundation
Donation Support Services Coordinator
Lifeline of Ohio
Columbus, Ohio
To learn more, see the program Hear Me: Patient Perspectives on PBC
In this podcast, expert faculty, Dr Stuart Gordon and Dr Nancy Reau, use an illustrative patient case to explore the roles of ALP and other biochemical markers in PBC management, and explain what to expect from treatment. Topics covered include:
- How baseline ALP can affect ALP normalization after second-line treatment with elafibranor and seladelpar
- Potential outcomes if ALP normalization cannot be achieved
- The importance of managing fatigue, pruritus, and sleep disturbances independently of the biochemical response
Presenters:
Stuart C. Gordon, MD
Professor of Medicine
Wayne State University School of Medicine
Director, Division of Hepatology
Henry Ford Health
Detroit, Michigan
Nancy Reau, MD
Professor of Medicine
Richard B. Capps Chair of Hepatology
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center
Chicago, Illinois
To learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.
In this podcast, expert faculty, Dr Stuart Gordon and Dr Nancy Reau discuss an illustrative patient case to demonstrate how they individualize primary biliary cholangitis (PBC) therapy for patients with cirrhosis. Topics covered include:
- AASLD guideline recommendations for second-line therapy for PBC
- Considerations when using newer agents for second-line treatment of PBC in patients with cirrhosis: elafibranor and seladelpar
Presenters:
Stuart C. Gordon, MD
Professor of Medicine
Wayne State University School of Medicine
Director, Division of Hepatology
Henry Ford Health
Detroit, Michigan
Nancy Reau, MD
Professor of Medicine
Richard B. Capps Chair of Hepatology
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center
Chicago, Illinois
To learn more about PBC management, check out our program,
Curbside Consults: Expert Insights on Challenges in PBC Management.
In this podcast, listen as experts Alan Bonder, MD, AGAF, and Aparna Goel, MD, discuss how they assess the symptoms of primary biliary cholangitis (PBC) and explore how new therapeutic agents may help alleviate symptom burden. Topics include:
- Strategies and tools for assessing pruritus
- Nonpharmacologic and pharmacologic management of pruritus
- Second-line agents and their impact on pruritus
- Investigational treatments for pruritus
Presenters:
Alan Bonder, MD, AGAF
Associate Professor of Medicine
Medical Director of Liver Transplant
Department of Gastroenterology
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts
Aparna Goel, MD
Associate Clinical Professor of Medicine
Division of Gastroenterology and Hepatology
Stanford University
Palo Alto, California
Content based on an online CME program supported by independent educational grants from Gilead Sciences, Inc., and Ipsen Biopharmaceuticals, Inc.
To learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.
How do you decide when to move from first-line to second-line treatment for primary biliary cholangitis (PBC)? In this podcast, listen as experts Alan Bonder, MD, AGAF, and Aparna Goel, MD, discuss this question and more, including:
- How and when to measure treatment response
- Evidence-based goals of therapy
- Considerations for second-line treatment
- New agents for second-line treatment: PPAR agonists
Presenters:
Alan Bonder, MD, AGAF
Associate Professor of Medicine
Medical Director of Liver Transplant
Department of Gastroenterology
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts
Aparna Goel, MD
Associate Clinical Professor of Medicine
Division of Gastroenterology and Hepatology
Stanford University
Palo Alto, California
Content based on an online CME program supported by independent educational grants from Gilead Sciences, Inc., and Ipsen Biopharmaceuticals, Inc.
To learn more about PBC management, check out our program,
Curbside Consults: Expert Insights on Challenges in PBC Management.
Supported by educational grants from Gilead Sciences, Inc. and Ipsen Biopharmaceuticals, Inc
In this podcast, Sonal Kumar, MD, MPH, meets with patient advocate Maria Morais to discuss actionable steps that healthcare providers can incorporate into the care of people with primary biliary cholangitis (PBC). Listen as they discuss:
- The chronic nature of PBC
- Going beyond biochemical markers to assess and address symptoms such as fatigue and pruritus
- The importance of referral to patient support groups
Presenters:
Sonal Kumar, MD, MPH
Assistant Professor of Medicine
Director, General Gastroenterology and Hepatology
Weill Cornell Medical College
New York, New York
Maria G. Morais, RN
VP Patient Advocacy
Canadian PBC Society
Toronto, Canada
To learn more, see the program Hear Me: Patient Perspectives on PBC
Listen in as rheumatology experts Alexis Ogdie, MD, MSCE, and Julia Swafford, PA-C, DFAAPA, discuss emerging therapies and strategies in managing patients with axial spondyloarthritis or psoriatic arthritis, including:
- The current treatment landscape (eg, small molecules, biologics)
- Risk factors to consider when prescribing JAK inhibitors
- Key considerations regarding comorbidities, especially in addressing depression, anxiety, or social ideation
- Nonpharmacologic options to improve treatment outcomes
- Shared decision-making strategies to enhance patients’ investment in their care
Presenter:
Alexis Ogdie, MD, MSCE
Director, Penn Psoriatic Arthritis and Spondylarthritis Program
Director, Penn Center for Clinical Epidemiology and Biostatistics
University of Pennsylvania
Philadelphia, Pennsylvania
Julia Swafford, PA-C, DFAAPA
President of SPAR
Bronson Battle Creek Rheumatology Specialists
Battle Creek, Michigan
Link to full program:
https://bit.ly/4gkTzSv
In this episode, Sonal Kumar, MD, MPH, discusses key findings from primary biliary cholangitis (PBC) studies presented at AASLD 2024, including:
- ELATIVE, a phase III trial of elafibranor for PBC
- RESPONSE, a phase III trial of seladelpar for PBC
- ASSURE, another phase III trial of seladelpar for PBC
Presenter:
Sonal Kumar, MD, MPH
Director, Clinical Gastroenterology and Hepatology
Assistant Professor of Medicine
Weill Cornell Medical College
New York, New York
Link to full program:
https://bit.ly/41tvSDu
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Clinical gaps in the treatment of pruritus in primary biliary cholangitis (PBC) remain. In this episode, taken from a recent symposium, Marlyn J. Mayo, MD; Stuart C. Gordon, MD; and Pam Rivard, RN, a person living with PBC, discuss emerging therapies currently in clinical trials for the management of this disease that can dramatically affect patients’ quality of life.
Listen as they discuss:
- Gaps in current management
- Patient perspectives: why we should not dismiss itching as an underlying psychologic problem
- PPAR agonists and how they affect pruritus
- BEZURSO and FITCH
- ELATIVE
- ENHANCE and RESPONSE
- IBATs (inhibitors of bile acid transport)
- GLIMMER
- Common questions
Presenters:
Marlyn J. Mayo, MD
Professor of Internal Medicine
Division of Digestive & Liver Diseases
UT Southwestern Medical Center
Dallas, Texas
Stuart C. Gordon, MD
Professor of Medicine
Wayne State University School of Medicine
Director, Division of Hepatology
Henry Ford Health
Detroit, Michigan
Pam Rivard, RN
Person living with PBC
Link to full program:
https://bit.ly/3Dnfb2E
Although there is currently no FDA-approved treatment for pruritus in primary biliary cholangitis (PBC), symptoms can be mitigated with nonpharmacologic or pharmacologic agents. In this episode, Marlyn J. Mayo, MD; Stuart C. Gordon, MD; and Pam Rivard, RN, a person living with PBC, discuss the clinical management of pruritus in PBC, including:
- Pruritus assessment tools
- Optimal use of tools, including frequency of assessment
- Current management of pruritus
- Nonpharmacologic interventions
- Pharmacologic agents
- Strategies to optimize assessment and management of pruritus
- Collaborative care
- Development of a treatment plan
- Ongoing assessment and adjustment of therapy
- Resources and support for patients
Presenters:
Marlyn J. Mayo, MD
Professor of Internal Medicine
Division of Digestive & Liver Diseases
UT Southwestern Medical Center
Dallas, Texas
Stuart C. Gordon, MD
Professor of Medicine
Wayne State University School of Medicine
Director, Division of Hepatology
Henry Ford Health
Detroit, Michigan
Pam Rivard, RN
Person living with PBC
Link to full program:
https://bit.ly/3Dnfb2E
In this episode, Marlyn J. Mayo, MD; Stuart C. Gordon, MD; and Pam Rivard, RN, a person living with primary biliary cholangitis (PBC), discuss the burden of pruritus in PBC and the impact it has on quality of life, including both physical and mental health, from a patient’s perspective.
Presenters:
Marlyn J. Mayo, MD
Professor of Internal Medicine
Division of Digestive & Liver Diseases
UT Southwestern Medical Center
Dallas, Texas
Stuart C. Gordon, MD
Professor of Medicine
Wayne State University School of Medicine
Director, Division of Hepatology
Henry Ford Health
Detroit, Michigan
Pam Rivard, RN
Person living with PBC
Link to full program:
https://bit.ly/4gDGDaB
In this episode, Christopher L. Bowlus, MD, discusses recent advances in the management of primary biliary cholangitis (PBC), including:
- Treatment goals
- Use of PPAR agonists for the treatment of PBC
- Clinical trial results for elafibranor (ELATIVE), seladelpar (RESPONSE), and bezafibrate (BEZURSO)
Presenter:
Christopher L. Bowlus, MD
Lena Valente Professor and Chief
Division of Gastroenterology and Hepatology
University of California Davis School of Medicine
Sacramento, California
Link to full program:
https://bit.ly/41tvSDu
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Listen as Elizabeth Kircher, DNP, and R. Hal Scofield, MD, discuss best practice approaches for the treatment of Sjögren’s syndrome and what’s on the horizon for future therapeutic options.
Topics include:
- Challenges in Sjogren’s Syndrome Diagnosis and Patient Understanding: Difficulties in explaining Sjogren’s syndrome diagnosis to patients unfamiliar with it and challenges in addressing the disease’s varied symptoms
- Patient Education and Communication: Strategies to prevent overwhelming patients during early visits and effective ways to address misconceptions
- Diagnostic Challenges and Misunderstandings: Differences between clinical and research criteria for diagnosis and the importance of understanding each
- Use of Ultrasound and Biopsy in Diagnosis: Benefits and limitations of ultrasound and biopsies in diagnosing Sjogren’s syndrome
- Multidisciplinary Care Barriers: Challenges in coordinating care among specialists such as ophthalmologists, dentists, and rheumatologists
- Symptomatic vs Disease-Modifying Treatments: Strategies for managing symptoms vs addressing the underlying disease with medications
- Long-term Medication and Risks: Considerations when prescribing long-term medications and immunosuppressive therapies
- Research and Emerging Therapies: Developments in Sjogren’s syndrome research, including promising medications in clinical trials
- Guideline Development and Patient Reassurance: The role of professional guidelines in shaping care and providing patients with reassurance
- Polypharmacy and Medication Reconciliation: The importance of pharmacist involvement in managing complex medication regimens for older patients
Faculty:
Elizabeth Kircher, DNP
R. Hal Scofield, MD
Member/Professor, Arthritis & Clinical Immunology
Oklahoma Medical Research Foundation
Professor, Department of Medicine, College of Medicine
University of Oklahoma Health Sciences Center
Associate Chief of Staff for Research
Oklahoma City US Department of Veterans Affairs Medical Center
Oklahoma City, Oklahoma
Link to full program:
https://bit.ly/3YKpsOE
In this CCO Nephrology podcast episode, hear from nephrologists Pietro Canetta, MD, MS, and Andy Bomback, MD, PhD, experts in clinical management and research on glomerular diseases as they discuss key updates in managing IgAN. Faculty highlight the importance of a comprehensive supportive care regimen to protect patients’ kidneys and prevent progression of disease. In addition, they review the merits and place in therapy of novel and emerging therapies.
Topics include:
- Supportive care as the foundation of IgAN management
- Place in therapy for new and emerging agents
- Targeted-release formulation of budesonide
- Endothelin receptor antagonists (eg, sparsentan)
- Factor B inhibitors (eg, iptacopan)
- The role of clinical trial involvement
Learn more about IgA nephropathy with educational activities and resources here:
- CME-certified text module with animated pathophysiology video and patient voice audio clip
- ClinicalThought commentaries
- Resources on IgAN from the American Kidney Fund
In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they discuss new and emerging therapies designed to target residual inflammatory risk associated with ASCVD and CKD.
Episode outline:
- Colchicine: inhibition of NLRP3 inflammasome assembly/activation
- Canakinumab (anti–IL-1β monoclonal antibody)
- Ziltivekimab (anti–IL-6 monoclonal antibody)
- Other emerging targets/therapies
To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:
- CME-certified text module with animated pathophysiology video and faculty voice audio clips
- ClinicalThought commentaries
- Podcast episode 1, discussing residual risk associated with systemic inflammation and the role of cardiologists and nephrologists in mitigating risk in ASCVD and CKD
- Podcast episode 2, discussing novel therapeutic approaches to address residual inflammatory risks in patients with ASCVD and CKD
In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they explore new and emerging strategies to target residual risk associated with systemic inflammation in patients with ASCVD and CKD.
Episode outline:
- The relationship among systemic inflammation, ASCVD, and CKD
- The role of cardiologists and nephrologists in screening and mitigating systemic inflammation
To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:
- CME-certified text module with animated pathophysiology video and faculty voice audio clips
- ClinicalThought commentaries
- Podcast episode 2, discussing novel therapeutic approaches to address residual inflammatory risks in patients with ASCVD and CKD
- Podcast episode 3, featuring faculty discussion of new and emerging therapies to target inflammatory risk in patients with ASCVD and CKD
In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they explore the pathophysiology and novel therapeutic strategies to target residual inflammatory risk associated with ASCVD and CKD.
Episode outline:
- Moving beyond lipid lowering to address residual inflammatory risk
- Novel anti-inflammatory targets for ASCVD
To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:
- CME-certified text module with animated pathophysiology video and faculty voice audio clips
- ClinicalThought commentaries
- Podcast episode 1, discussing residual risk associated with systemic inflammation and the role of cardiologists and nephrologists in mitigating risk in ASCVD and CKD
- Podcast episode 3, featuring faculty discussion of new and emerging therapies to target inflammatory risk in patients with ASCVD and CKD
In this CCO Nephrology podcast episode, hear from Kelly Chen, a nephrology nurse practitioner and patient living with IgA nephropathy, as she discusses her experiences with Dr Pietro Canetta, Associate Professor of Medicine at Columbia University and expert in glomerular diseases.
Episode outline:
- Seeking and obtaining an IgAN diagnosis
- Patient self-advocacy
- Individualizing IgAN treatment plans
- Clinical trial involvement
- Burdens of IgAN: physical, emotional, social, and beyond
To learn more about IgA nephropathy, find more educational activities and resources with the links below:
- CME-certified text module with animated pathophysiology video and patient voice audio clips
- ClinicalThought commentaries
- Resources on IgAN from the American Kidney Fund
In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:
- Patient subgroups to consider for treatment outside guideline criteria
- Adverse event and cost-effectiveness considerations
- Integration of patient perspectives in wider treatment
Presenters:
Mark S. Sulkowski, MD, FIDSA, FAASLD
Professor of Medicine
Director, Division of Infectious Diseases, Johns Hopkins Bayview Medical Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
Tatyana Kushner, MD, MSCE
Associate Professor
Division of Liver Diseases
Icahn School of Medicine at Mount Sinai
New York, New York
Paul Y. Kwo, MD
Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California
Jacki Chen, PhD
Patient Advocate
Link to full program:
https://bit.ly/3TuqFHI
Link to the slides:
https://bit.ly/4a60GM4
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Arun B. Jesudian, MD, and Mazen Noureddin, MD, MHSc, discuss the expert-informed clinical pathway for the multidisciplinary care of patients with MASLD or MASH, current and emerging therapeutics, and management optimization strategies.
Presenters:
Arun B. Jesudian, MD
Associate Professor of Clinical Medicine
Division of Gastroenterology and Hepatology
Weill Cornell Medicine
New York, New York
Mazen Noureddin, MD, MHSc
Professor of Medicine
Houston Methodist Hospital
Director
Houston Research Institute
Houston, Texas
Content based on an online CME program supported by independent educational grants from Novo Nordisk.
To view the full program on “Clinical Pathways: Multidisciplinary Approach to Managing Metabolic Dysfunction‒Associated Steatohepatitis,” including 4 CME/CE-certified text modules with accompanying slidesets, 4 ClincalThought commentaries, and a downloadable infographic resource on the AGA MASLD MASH Clinical Care Pathway, visit clinicaloptions.com or click on the link below.
Link to full program:
https://bit.ly/3Tyu7At
In this episode, Jennifer Green, MD, and Carol Hatch Wysham, MD, break down the latest headlines on incretin-based therapies and how to address these topics with patients. Their discussion includes:
- Beneficial effects beyond glycemic control
- Adverse events and how to manage them
- Non- or partial responders and the importance of setting expectations with patients
- Weight rebound when discontinuing therapy
- Medication access issues related to cost and drug availability
Presenters:
Jennifer Green, MD
Professor of Medicine
Division of Endocrinology and Duke Clinical Research Institute
Duke University School of Medicine
Durham, North Carolina
Carol Hatch Wysham, MD
Clinical Professor of Medicine
Clinical Endocrinologist
MultiCare/Rockwood Clinic
Spokane, Washington
Link to online program:
https://bit.ly/48b6XnW
In this episode, Douglas Dieterich, MD, leads a panel discussion with Camilla S. Graham, MD, MPH, and Robert Wong, MD, MS, to consider advantages and barriers to universal screening for chronic HBV infection and universal HDV screening in adults with HBV in the United States. Topics include:
- Updated CDC recommendations for one-time universal screening for HBV
- Addressing patient-, provider-, and system-level barriers to universal HBV screening
- Best practices for implementation of HDV screening
Presenters:
Douglas Dieterich, MD
Director, Institute for Liver Medicine
Professor of Medicine
Division of Liver Diseases
Mount Sinai School of Medicine
New York, New York
Camilla S. Graham, MD, MPH
Co-Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts
Robert Wong, MD, MS
Clinical Associate Professor
Division of Gastroenterology and Hepatology
Stanford University School of Medicine
Palo Alto, California
Link to full program:
https://bit.ly/3TuqFHI
Link to the slides:
https://bit.ly/4atS42z
In this podcast episode, Aline Charabaty, MD, AGAF, FACG, and Marla Dubinsky, MD, discuss how women in gastroenterology (GI) can find their “friendtors” and build a strong network of mentors, sponsors, and allies. Although there may be many barriers for women in the GI medicine specialty, these experienced leaders have useful tips to help emerging healthcare professionals avoid internalizing these challenges and strategically focus on accomplishing their goals.
Presenters:
Dr Aline Charabaty is an Assistant Professor of Medicine at Johns Hopkins School of Medicine, the Clinical Director of the IBD Centre at Johns Hopkins Sibley Memorial Hospital in Washington, DC, and the Co-Founder of Scrubs & Heels.
Aline Charabaty, MD, AGAF, FACG: consultant/advisor/speaker: AbbVie, Bristol Myers Squibb, Janssen, Lilly, Pfizer, Takeda.
Dr Marla Dubinsky is a Professor of Pediatrics and Medicine at Mount Sinai in New York, Chief of Division of Pediatric GI and Nutrition at Mount Sinai Kravis Children's Hospital, and the Co-Director of the Susan and Leonard Feinstein IBD Clinical Centre. Dr Dubinsky is also the Director of the Marie and Barry Lipman IBD Preconception and Pregnancy Clinic. She is also an innovator and the Co-Founder of Trellus Health, providing personalized resilience coaching for people living with IBD. She received the Sherman Prize in 2022, which recognized her outstanding achievement in the field of IBD. In addition, she served as the Co-Chair for our inaugural Scrubs & Heels Leadership Summit in 2022.
Marla Dubinsky, MD: consultant/advisor/speaker: AbbVie, Abivax, AstraZeneca, Bristol Myers Squibb, Janssen, Lilly, Merck, Pfizer, Prometheus Biosciences, Takeda.
Episode outline:
- Overview of barriers faced by women in GI
- Impact of failing to adequately address these barriers
- Defining the roles of mentors, sponsors, and allies
- Important qualities of mentors, sponsors, and allies
- Role models vs peer mentors
Other program activities:
- Full Program: Equipped and Empowered: Thriving as Women in GI
- Podcast 2: Embracing Your Value: Tools and Strategies for Optimizing Professional Growth and Development
- Podcast 3: Being Your Full Self: Pursuing Work–Life Balance
- ClinicalThought: Expert Commentary on Thriving as Women in GI
After selecting the “Continue to Post Test” button:
To receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select 1 best answer for each question. When you have completed all the questions, press the "Continue" button at the bottom
In this podcast episode, Anita Afzali, MD, MPH, MHCM, FACG, AGAF, and Aja McCutchen, MD, discuss how women in gastroenterology (GI) can embrace and enhance their value. These inspiring GI medicine experts propose a practical formula that involves ongoing, careful self-reflection and asking yourself how your strengths, core values, and interests can be aligned with professional endeavors. In addition, self-advocacy and self-allyship can serve as harmonious tools to drive action and positive change.
Presenters:
Dr Anita Afzali is a Professor of Clinical Medicine, Interim Division Director of the Division of Digestive Diseases, Executive Vice Chair of Medicine in the Department of Internal Medicine, and the Associate Chief Medical Officer of the UC Health system in Cincinnati, Ohio. She is also a Co-Founder of Scrubs & Heels.
Anita Afzali, MD, MPH, MHCM, FACG, AGAF: consultant: AbbVie, Bristol Myers Squibb, Gilead Sciences, Janssen, Lilly, Pfizer, Takeda; provider of non-CME/CE services: AbbVie, Janssen, Pfizer, Takeda.
Dr Aja McCutchen is a Partner and Physician Executive at Atlanta Gastroenterology Associates, a division of United Digestive in Atlanta, Georgia, and served as Co-Chair at the Scrubs & Heels 2023 Leadership Summit.
Aja McCutchen, MD: consultant/advisor/speaker: Eli Lilly, Modify Health, Redhill Biopharm, Sanofi Regeneron, Takeda.
Episode outline:
- Understanding and establishing your own market value; bringing that to your own organization
- Consequences of being ill-equipped to pursue professional growth and development
- Advocating for the value you bring to the profession
- Negotiation as a form of self-allyship
- Negotiation categories to help support career success and protect work–life balance
Other program activities:
- Full Program: Equipped and Empowered: Thriving as Women in GI
- Podcast 1: Finding Your Friendtors: Mentors, Sponsors, and Allies
- Podcast 3: Being Your Full Self: Pursuing Work–Life Balance
- ClinicalThought: Expert Commentary on Thriving as Women in GI
To receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select 1 best answer for each question. When you have completed all the questions, press the "Continue" button at the bottom.
In this podcast episode, Aline Charabaty, MD, AGAF, FACG, and Christina Tennyson, MD, DipABLM, discuss how women in gastroenterology (GI) can fight burnout and establish a work–life balance that meets their needs. Tune in to learn how to say no, about the importance of saying yes to meaningful things that will advance your career and bring you joy, and get essential tips for well-rounded and ongoing self-care.
Presenters:
Dr Aline Charabaty is an Assistant Professor of Medicine at Johns Hopkins School of Medicine, the Clinical Director of the IBD Centre at Johns Hopkins Sibley Memorial Hospital in Washington, DC, and the Co-Founder of Scrubs & Heels.
Aline Charabaty, MD, AGAF, FACG: consultant/advisor/speaker: AbbVie, Bristol Myers Squibb, Janssen, Lilly, Pfizer, Takeda.
Dr Christina Tennyson is a gastroenterologist with expertise and certification in nutrition, lifestyle medicine, and integrative medicine. She started her career in academia at Columbia University in New York before joining the Augusta Health Digestive Wellness program in the Virginia Shenandoah Valley, where she is engaged in a multidisciplinary program that includes culinary medicine classes and farm workshops for patients.
Christina Tennyson, MD, DipABLM, has no relevant financial relationships to disclose.
[Link to: https://scrubsandheels.com/]
Episode outline:
- Variables that contribute to burnout
- Strategies to protect your time
- Vetting collaborative projects
- Requesting flexible schedules, part-time work, maternity leave
- Charting your own career path
- Prioritizing personal time
- Preserving friendships, hobbies
- Leave work at work
Other program activities:
- Full Program: Equipped and Empowered: Thriving as Women in GI https://bit.ly/3Zmqy1I]
- Podcast 1: Finding Your Friendtors: Mentors, Sponsors, and Allies https://bit.ly/3LuKzO6
- Podcast 2: Embracing Your Value: Tools and Strategies for Optimizing Professional Growth and Development https://bit.ly/3RsFl9i
- ClinicalThought: Expert Commentary on Thriving as Women in GI https://bit.ly/48oi5iS
Link to CME: Claim Credit: https://bit.ly/48oi5iS
[After selecting the “Continue to Post Test” button:]
To receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select 1 best answer for each question. When you have completed all the questions, press the "Continue" button at the bottom.
This podcast episode is part of a multimedia program discussing the impact of health disparities in anemia of chronic kidney disease (CKD) on patient outcomes. Tune in to hear Santosh Saraf, MD, and Milda Saunders, MD, MPH, highlight mitigation strategies to improve screening and management. The overview will include:
- The definition of CKD and the relative prevalence in specific minority groups
- How health disparities affect CKD-related clinical and patient outcomes
- Appropriate screening techniques to diagnose patients with anemia of CKD
- Strategies to address health disparities to improve patient outcomes in the management of anemia of CKD
Presenters:
Santosh Saraf, MD
Associate Professor of Medicine
Division of Hematology and Oncology
Department of Medicine
University of Illinois at Chicago
Chicago, Illinois
Milda Saunders, MD, MPH
Associate Professor of Medicine
Department of Medicine
University of Chicago
Chicago, Illinois
To view other program offerings, including a CE-certified on-demand webcast, a ClinicalThought commentary, and to download slides, visit:
https://bit.ly/3iL07S0
In this episode, listen as Karen H. Costenbader, MD, MPH, and Brad H. Rovin, MD, answer key questions about identifying patients at high risk for lupus nephritis, whether an elevated serum creatinine always signals lupus nephritis, the safety of newer therapies for lupus in women who are pregnant or breastfeeding, and the possibility of using SGLT2 inhibitors in patients with lupus nephritis.
Presenters:
Karen H. Costenbader, MD, MPH
Professor of Medicine
Department of Medicine
Harvard Medical School
Director, Lupus Program
Division of Rheumatology, Inflammation and Immunity
Brigham and Women’s Hospital
Boston, Massachusetts
Brad H. Rovin, MD
Professor and Director, Division of Nephrology
The Lee A. Hebert Professor of Nephrology
Medical Director, The Ohio State Center for Clinical Research Management
The Ohio State University Wexner Medical Center
Columbus, Ohio
Review the downloadable slidesets at:
https://bit.ly/3mlHOla
Link to full program:
https://bit.ly/3aC2NNL
In this episode, David S. Kountz, MD, discusses with Keith C. Ferdinand MD, FACC, FAHA, a patient case in which health disparities affected NVAF care and provides patient, provider, and health-system level strategies to address these disparities to improve NVAF-related cardiovascular outcomes.
Presenters
Keith C. Ferdinand, MD, FACC, FAHA
Professor of Medicine
Tulane Heart and Vascular Institute
Tulane University School of Medicine
New Orleans, Louisiana
David S. Kountz, MD
Professor of Medicine
Department of Medicine
Hackensack Meridian School of Medicine
Nutley, New Jersey
Link to full program:
https://bit.ly/3MbIfZI
In this episode, Keith C. Ferdinand MD, FACC, FAHA, discusses with David S. Kountz, MD, a patient case in which health disparities affected NVAF care and provides strategies to address low health literacy and patient access to direct-acting oral anticoagulant to improve NVAF-related cardiovascular outcomes.
Presenters
Keith C. Ferdinand, MD, FACC, FAHA
Professor of Medicine
Tulane Heart and Vascular Institute
Tulane University School of Medicine
New Orleans, Louisiana
David S. Kountz, MD
Professor of Medicine
Department of Medicine
Hackensack Meridian School of Medicine
Nutley, New Jersey
Link to full program:
https://bit.ly/3MbIfZI
In this episode, Karen H. Costenbader, MD, MPH, and Brad H. Rovin, MD, discuss health disparities in systemic lupus erythematosus and lupus nephritis. Topics include:
- Disproportionate prevalence among marginalized groups in the United States
- Lupus-related social determinants of health
- Challenges with medication adherence
- Strategies to reduce these disparities
Presenters:
Karen H. Costenbader, MD, MPH
Professor of Medicine
Department of Medicine
Harvard Medical School
Director, Lupus Program
Division of Rheumatology, Inflammation and Immunity
Brigham and Women’s Hospital
Boston, Massachusetts
Brad H. Rovin, MD
Professor and Director, Division of Nephrology
The Lee A. Hebert Professor of Nephrology
Medical Director, The Ohio State Center for Clinical Research Management
The Ohio State University Wexner Medical Center
Columbus, Ohio
This episode is part of a larger program titled, “Lupus and Lupus Nephritis: Improving Outcomes and Reducing Disparities.” To access the full program, follow this link:
https://bit.ly/3PWAzNU
This podcast is the second in a series of 3 featuring an expert multidisciplinary panel of faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, Laura Ross PA-C, CLS, dives deeper into the impacts of SODH on NVAF care and provides strategies to address to improve patient care and clinical outcomes in NVAF.
Review the downloadable slideset and the full program at:
https://bit.ly/3yYXP8e
This podcast is the first in a series of 3 featuring an multidisciplinary panel of expert faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, David S. Kountz, MD, provides a detailed explanation of the atrial fibrillation paradox and data on the impacts of SDOH on NVAF CV-related outcomes.
Review the downloadable slideset and the full program at:
https://bit.ly/3yYXP8e
This podcast is the third in a series of 3 featuring an expert multidisciplinary panel of faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, Keith C. Ferdinand, MD, FACC, FAHA, details the effects of SDOH on anticoagulation prescribing in NVAF and provides an overview of areas for future study.
Review the downloadable slideset and the full program at:
https://bit.ly/3yYXP8e
In this episode, Dr. Stanley Cohen, Dr. Sheetal Desai, and Dr. Eric Ruderman discuss the recent changes in rheumatoid arthritis treatment options, reviewing the landscape of targeted DMARDs and JAK inhibitors, including:
- Kinase signaling
- JAK inhibitor activity and signaling
- JAK selectivity
Presenters:
Stanley B. Cohen, MD
Clinical Professor
Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director
Division of Rheumatology
Presbyterian Hospital
Co-Medical Director
Metroplex Clinical Research Center
Dallas, Texas
Sheetal Desai, MD, MSEd
Chief of Rheumatology
Program Director
University of California, Irvine
Irvine, California
Eric M. Ruderman, MD
Professor, Associate Chief
Division of Rheumatology
Northwestern University Feinberg School of Medicine
Clinical Practice Director
Northwestern Medical Group
Chicago, Illinois
Download the accompanying slides at:
https://bit.ly/3447Gce
See the interactive video at:
https://bit.ly/3oCOtpV
In this episode, Dr. Stanley Cohen, Dr. Sheetal Desai, and Dr. Eric Ruderman interpret the latest safety and efficacy data for JAK inhibitors in RA, including the ORAL, BEACON, BEAM, SELECT, and FINCH series in
- bDMARD-IR
- MTX-IR
- MTX naive
Also included is an in-depth discussion of JAK safety, including MACE and VTE, and use in the clinic including JAK cycling
Presenters:
Stanley B. Cohen, MD
Clinical Professor
Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director
Division of Rheumatology
Presbyterian Hospital
Co-Medical Director
Metroplex Clinical Research Center
Dallas, Texas
Sheetal Desai, MD, MSEd
Chief of Rheumatology
Program Director
University of California, Irvine
Irvine, California
Eric M. Ruderman, MD
Professor, Associate Chief
Division of Rheumatology
Northwestern University Feinberg School of Medicine
Clinical Practice Director
Northwestern Medical Group
Chicago, Illinois
Download the accompanying slides at:
https://bit.ly/37bm6cJ
See the interactive video at:
https://bit.ly/3oCOtpV
In this episode, Dr. Stanley Cohen, Dr. Sheetal Desai, and Dr. Eric Ruderman discuss how to translate information on JAK inhibitors and other treatments for your patient population in the clinic, covering practical tips on using:
- Treat-to-target approaches
- Disease activity measures
- Shared decision-making
- Decision aids
- Translating clinical trial evidence
Also included are the experts’ answers to questions from clinicians like you.
Stanley B. Cohen, MD
Clinical Professor
Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director
Division of Rheumatology
Presbyterian Hospital
Co-Medical Director
Metroplex Clinical Research Center
Dallas, Texas
Sheetal Desai, MD, MSEd
Chief of Rheumatology
Program Director
University of California, Irvine
Irvine, California
Eric M. Ruderman, MD
Professor, Associate Chief
Division of Rheumatology
Northwestern University Feinberg School of Medicine
Clinical Practice Director
Northwestern Medical Group
Chicago, Illinois
Download the accompanying slides at:
https://bit.ly/3gHDE3s
See the interactive video at:
https://bit.ly/3oCOtpV
What should our patients with NAFLD eat? Listen as expert hepatologist Rotonya Carr, MD, explores the evidence behind different diets in NAFLD/NASH.
Download the slides from this podcast at:
https://bit.ly/3gpzuMj
See more NASH topics at:
https://bit.ly/3ezkBq6
Hear Brent A. Neuschwander-Tetri, MD, explore NASH screening and the interplay among NAFLD, metabolic syndrome, CV risk, and diabetes risk, including:
- Should We Screen for NASH?
- Role of obesity and type 2 diabetes mellitus
- Cardiovascular Risk in NAFLD/NASH
- How to Evaluate for NAFLD/NASH
- Biomarkers
- Imaging
- When/whom to biopsy?
- Management in Multidisciplinary Settings
Download the slides from this podcast at:
https://bit.ly/2ZBvVvy
See more NASH topics at:
https://bit.ly/3ezkBq6
Hear Stephen A. Harrison, MD, COL (Ret.), FAASLD, weigh the latest perspectives on wet biomarkers, imaging, and combination tests in NASH, including their use in:
• Diagnosis of NASH patients with NAS ≥ 4 and fibrosis ≥ F2
• Assessment of therapeutic response
• Assessment of long-term patient outcomes
Download the slides from this podcast at:
https://bit.ly/3il5rqG
See more NASH topics at:
https://bit.ly/3ezkBq6
Hear Philip N. Newsome, PhD, FRCPE, discussavailable approaches to managing NASH, including lifestyle, vitamin E, and compounds that target insulin resistance, including:
- Recommended Pharmacologic Therapies for NASH
- Pioglitazone
- Vitamin E
- Optimal Diabetes Therapies in NAFLD/NASH
- Weight Loss
- Liver Health
- Surgical Approaches to Weight Loss and Effect on Liver
Download the slides from this podcast at:
https://bit.ly/3ig0r6x
See more NASH topics at:
https://bit.ly/3ezkBq6
Hear Dr. Katherine Wagner *and *Dr. Richard Finkle discussnovel gene-based approaches to treating patients with Duchenne muscular dystrophy and limb girdle muscular dystrophies. The latest clinical trial data and gene therapy considerations for product selection including AAV mini-dystrophin and other investigational therapies will be explored.
Download the slides from this podcast at:
https://bit.ly/2zZgB2X
See more neurology topics at:
https://bit.ly/3eAMVby
Hear Philip N. Newsome, PhD, FRCPE, discuss the agents in late-phase clinical trials and their potential use in the treatment of NASH and fibrosis, including those in phase III such as:
- Obeticholic acid
- Cenicriviroc
- Resmetirom
- Aramchol
Download the slides from this podcast at:
https://bit.ly/3eJYKvW
See more NASH topics at:
https://bit.ly/3ezkBq6
Link to CME: Claim Credit - https://bit.ly/3dQPQwT .
Continuous glucose monitoring (CGM) is a great tool that improves clinical outcomes for people with diabetes; these individuals are often happy to get this new technology.
However, there can be some initial barriers that both people with diabetes and clinicians need to overcome.
BARRIER 1: Wearing something on the body so other people know the person has diabetes.
SOLUTION 1: Let the person see the size of different devices through demonstrations and show possible discreet places on the body where they can be worn.
- Consider starting with a professional CGM, owned by the clinic and borrowed by the individual for up to 14 days, so that he or she can get a feel for what it is like.
- Consider a CGM that can be integrated with a smart pen instead of an insulin pump, so the individual has only 1 device to wear.
BARRIER 2: Cost of the CGM.
SOLUTION 2: Find out insurance requirements to see if the CGM can be covered and what is required for coverage.
- A disposable sensor is a lower cost option. There are coupons available and some pharmacies sell for lower costs.
- Professional CGM is an underused insurance benefit that is often covered multiple times per year if used on a short- term basis.
BARRIER 3: Too much information from CGM can be overwhelming for the individual.
SOLUTION 3: Make sure alarms and alerts are set appropriately to avoid alarm fatigue—have the alerts go off when it matters most, like during hypoglycemia. Look at the device at key times only, like before meals, before bedtime, and before activities like exercising and driving, and utilize CGM to determine glycemic trends.
BARRIER 4: Clinicians are hesitant to embrace CGM technology.
SOLUTION 4: There are various resources available to help clinicians understand CGM technology and to assist in integrating CGM into their practice settings.
- Online tutorials, industry representatives, and diabetes care and education specialists can help clinicians understand how to start people with diabetes on CGM and how to interpret the data.
- CPT codes are now available to help support the cost of additional staff to train the individual on the devices and cover the cost of review and interpretation.
Presenters:
Carla Cox PhD, RD, FAADE
Certified Diabetes Educator and Clinical Dietitian
Mountain Vista Medicine
South Jordan, Utah
Diana Isaacs PharmD, BCPS, BCACP, BC-ADM, CDE
Clinical Pharmacy Specialist/CGM Program Coordinator
Department of Endocrinology, Diabetes, and Metabolism
Cleveland Clinic Diabetes Center
Cleveland, Ohio
Provided by the Endocrine Society in collaboration with the ADCES.
Supported by an educational grant from Lilly.